STOCK TITAN

Century Therapeutics, Inc. - $IPSC STOCK NEWS

Welcome to our dedicated page for Century Therapeutics news (Ticker: $IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Century Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Century Therapeutics's position in the market.

Rhea-AI Summary
Century Therapeutics (IPSC) to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference. Management team to discuss iPSC-derived cell therapies in immuno-oncology. Event replay available on company website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
conferences
-
Rhea-AI Summary
Century Therapeutics, Inc. (NASDAQ: IPSC) reported financial results and business highlights for Q3 2023, including the appointment of a new CEO, presentation of data at ASH Annual Meeting, expanded license agreements with FUJIFILM Cellular Dynamics, and ending the quarter with $284.3 million in cash, cash equivalents, and investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.13%
Tags
-
Rhea-AI Summary
Century Therapeutics, Inc. (NASDAQ: IPSC) announced the appointment of Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer and member of the Board. With over 20 years of experience in the healthcare industry, Dr. Pfeiffenberger will bring strategic leadership and operational acumen to Century. He will be replacing Greg Russotti, Ph.D., who will assume the role of Chief Technology and Manufacturing Officer. Dr. Pfeiffenberger's extensive experience includes leadership roles at Neogene Therapeutics and Bristol Myers Squibb.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.13%
Tags
management
Rhea-AI Summary
Century Therapeutics, Inc. (NASDAQ: IPSC) and FUJIFILM Cellular Dynamics, Inc. announce a new worldwide license agreement and expansion of existing licenses for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases. The licenses will enable the development of treatments for conditions such as type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis. The agreements also include provisions for milestone payments and royalties. The companies aim to leverage iPSC-derived cell therapies to address the unmet needs in the treatment of immune-mediated diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.13%
Tags
none
-
Rhea-AI Summary
Century Therapeutics announces upcoming presentation of initial data from Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas. Preliminary data shows complete response in a patient following four cycles of CNTY-101. The therapy is well tolerated and supports a multi-dosing strategy. Additional data to be presented at ASH conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.68%
Tags
conferences clinical trial
-
Rhea-AI Summary
Century Therapeutics CEO to participate in fireside chat at Chardan conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.72%
Tags
-
Rhea-AI Summary
Century Therapeutics, Inc. reported financial results for Q1 2023 and provided business highlights. The company presented preclinical data supporting the selection of CNTY-101 as its lead product candidate. They remain on track to report initial data from the ongoing Phase 1 ELiPSE-1 trial of CNTY-101 by year end. The company ended Q1 2023 with $334.8 million in cash, cash equivalents, and investments, and expects its cash runway to extend into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.29%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.91%
Tags
management
Century Therapeutics, Inc.

Nasdaq:IPSC

IPSC Rankings

IPSC Stock Data

196.40M
26.36M
36.38%
50.41%
2.54%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
PHILADELPHIA

About IPSC

Century Therapeutics, Inc. specializes in adult stem cells to develop curative cell therapy products for cancer that overcome the limitations of first generation cell therapies as well as provides testing and research services.